Log in

Company updateEconomic Times

Glenmark launches generic Inlyta for kidney cancer in US

Positive+192 sources

GreyOak summary

Glenmark Pharmaceuticals launched generic Axitinib tablets in the US to treat advanced renal cell carcinoma. The product is a generic equivalent of Pfizer's Inlyta. According to IQVIA data, annual sales of Inlyta in the US were approximately USD 538.4 million for the period ended September 2026.

What it affects

Source

Read the original at Economic Times

More Glenmark Pharmaceuticals news

All Glenmark Pharmaceuticals news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy